|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007134,
umls-concept:C0017262,
umls-concept:C0024432,
umls-concept:C0027651,
umls-concept:C0030705,
umls-concept:C0032145,
umls-concept:C0033325,
umls-concept:C0042071,
umls-concept:C0071216,
umls-concept:C0185117,
umls-concept:C0332281,
umls-concept:C1707520,
umls-concept:C2911684
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2005-7-11
|
|
pubmed:abstractText |
Urokinase-type plasminogen activator (uPA) has an important role in tumor progression through the degradation of extracellular matrix. In addition, uPA receptor (uPAR) and plasminogen activator inhibitors (PAIs), composed of PAI-1 and 2, are also known to affect such activities. Tumor associated macrophage (TAM) is an important regulator of tumor progression that is associated with the uPA system in various cancers. However, to our knowledge the clinical significance of PAI-2 and the relationship between the uPA system and TAM in human renal cell carcinoma (RCC) tissues have not been investigated. We investigated and clarified these issues.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0022-5347
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
174
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
461-5
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16006865-Aged,
pubmed-meshheading:16006865-Aged, 80 and over,
pubmed-meshheading:16006865-Carcinoma, Renal Cell,
pubmed-meshheading:16006865-Female,
pubmed-meshheading:16006865-Humans,
pubmed-meshheading:16006865-Immunohistochemistry,
pubmed-meshheading:16006865-Kidney Neoplasms,
pubmed-meshheading:16006865-Macrophages,
pubmed-meshheading:16006865-Male,
pubmed-meshheading:16006865-Middle Aged,
pubmed-meshheading:16006865-Multivariate Analysis,
pubmed-meshheading:16006865-Plasminogen Activator Inhibitor 2,
pubmed-meshheading:16006865-Plasminogen Inactivators,
pubmed-meshheading:16006865-Prognosis,
pubmed-meshheading:16006865-Proportional Hazards Models,
pubmed-meshheading:16006865-Receptors, Cell Surface,
pubmed-meshheading:16006865-Receptors, Urokinase Plasminogen Activator,
pubmed-meshheading:16006865-Urokinase-Type Plasminogen Activator
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
|
|
pubmed:affiliation |
Department of Urology, Nagasaki University Graduate School of Medicine, Nagasaki, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
